Patients undergoing cataract surgery at Rush Eye Associates now have access to a breakthrough “trifocal” lens implant called the AcrySof® IQ PanOptix® Trifocal Intraocular Lens that recently received approval by the Food & Drug Administration for implantation in the United States. During investigational clinical trials, PanOptix patients were able to enjoy uninterrupted vision at near, intermediate and distance. The results also showed high patient satisfaction with more than ninety-five percent of PanOptix patients saying they would choose the same lens again.
The PanOptix lens is the first trifocal lens implant of its kind capable of delivering a unique combination of near, intermediate and distance vision to patients while significantly reducing your need for glasses after cataract surgery. This trifocal lens implant is designed for patients with active lifestyles who require good vision at all ranges. This would include everything from viewing mobile devices and computer screens to intermediate and high-quality distance vision in a range of lighting conditions.
Medicare allows patients to upgrade their vision using advanced lens implant technology like the PanOptix lens. The standard intraocular lens implant is covered by medical insurance (including Medicare), but the PanOptix lens technology is not covered. Patients are responsible for the out-of-pocket costs associated with the upgraded premium lens implant technology. See what financing options are available.